have industry. afternoon Thank events significant Recent a times. and joining us ongoing you, related especially our world around appreciate created We extraordinary uncertainty to good Nick challenging pandemic and on COVID-XX during and within you everyone. degree our these the call the of today,
also having our the is COVID-XX our made progress on with communicate we us our backdrop, pipeline to shareholders on to is an you across it impact think update for have specifically. important provide the that business Against programs and very we to
relentless in for novel impacts, those the from was The patients year milestones by challenging made CNS support of of by XXXX. I'd with developing our therapies disorders. into mission we our and in getting numerous like to clinical execution team significant marked review progress the to Before suffering
centered to At all into of the set of for of Thanks goals clinical those initiated we X our that advancing around accomplished last goals candidates development studies Phase the three we outset last product X and year, terrific efforts four new Phase team, our study. ambitious year. clinical stage
studies throughout ability compound These development I characterize evaluate address and of pain, progress. in everything our PTSD unmet the the and novel the achieve to will needs am to of year that of teams very chronic accomplished impairment. the cognitive proud significant areas
been our momentum across important It and is have our good we XXXX continued also making each progress to have into note of that studies.
Of course, in the decisions regarding we of pandemic, throughout like and by our industry activities. light some our experiencing we have COVID-XX made introduced challenges development many these certain are clinical challenges
people compound XXXX NYX-XXX, Let’s X in is In in along. began that study and with an an on furthest patients by in The first NYX-XXX array with patients evaluating update of we PTSD. the our PTSD. the intended start exploratory NYX-XXX Phase for study evaluate with mechanism in effects to as on study XXX of symptoms of PTSD initial, broad of unique the a is approximately novel time experienced
To all by the progressing XX% and in target study date, have enrollment tracking has and our we approximately of metrics enrollment well. been achieved
manage far disruptions by some so been have been pandemic, there have COVID-XX them. site we and While at mitigate on brought to the the level able
feasible. are required to sites of continuity, and with our patient investigator develop delivery virtual accommodations participant follow-up as support where working to appropriate these home drug are and We study such
moving and study enrollment sites investigators of keep the this our Given needs welfare at some PTSD, dedication of with and patients time, study we patient of [ph] specific continue in forward. interest it we feel is the perseverance of the to appreciate in this and to this
into will patients responsible to new make and enroll so every remains long and study do as feasible. We effort continue this as this to
of dialogue study, the will and continuous of evaluation our to COVID-XX CROs well-being our this close with and in including remain sites patient primary vigilant [ph] We impacts safety focus and on
uncertainty on completion the guidance COVID-XX, ongoing around study timing of anticipate we providing from a readout the future and at Given updated of date. data this expected
which Now read in let's diabetic discuss out fibromyalgia. in X studies Phase first two development neuropathy, NYX-XXXX, XXXX indications, patients is these X in conditions. pain our we and peripheral Phase painful clinical chronic with In
validated the biomarker effects central evaluated of first processing. study Our of on pain neuro-imaging in fibromyalgia NYX-XXXX
XXXX in and changes were meaningful correlated We resulted and these effects significant that biomarker fibromyalgia in statistically significant saw other that improvement pain statistically these clinically with in biomarkers symptoms. and
our we pain, compelling inform our we and criteria patients helped study reduction NYX-XXXX thickness study saw other of run painful dose Along of The chronic which design pain inclusion that exclusion patient for in selection, segments. in current with in validating aimed and side, these parameters at studies first DPN. are
enhances important and and brain receptor-mediated in Its on have who experienced that gets addresses improvement It processing tremendously observed imaging be in information pain Together, through into initial objectively activity patients compelling translates have into activity symptom these NYX-XXXX. of provided NMDA central abnormalities pain can that pathways. chronically. studies the signals
studies, to in first in and intended one we what studies on and studies. the have leveraging effect the these actively the We've screening sites those studies. Both studies fibromyalgia in Based period. validate week learned of a and involving in initial initiated are was and we over late two designed studies, start-up and painful X to all completed follow-up patients these XX been Xb evaluate in XXXX one Phase Phase DPN observed efficacy NYX-XXXX work of in the safety
patients COVID-XX temporarily both suspended on of to the enrollment into the of enrollments these caused screening and March by However, studies. new pandemic, XXtj in of challenges we light
in and forth in conducting studies, already FDA guidelines accordance Importantly, the patients have studies. and that in with enrolled may the continue set further by CDC protocols clinical these
these and a And future the CROs with anticipate we readouts to [ph] when studies resume appropriate guidance our the expected site at updating to We of timing it will our enrollment. around enrollment date and situation active closely this following top line maintain is monitor from continue very determine of the studies. commencement in these dialogue to
let's discuss NYX-XXX cognitive our treatment disease. associated of Finally, the of for Parkinson's with development impairment
published Movement translatable of with validated The Disorders, saw in in deficits. non-human recently primates, cognitive model reversal results a Journal we highly striking As durable in NYX-XXX we and remarkable showing and
This on with potential to in those X the Parkinson's last Based enthusiastic first for were Phase cognitive cognitive will of NYX-XXX evaluate study exploratory impairment time. data, Parkinson's safety excited patients in and the our NYX-XXX we very and initiate December. of patients study benefits first mild
are COVID-XX medical patients, new vulnerable of suspend study to However, the have Despite on may in we those due suspension patients more on and consistent study the to of to the enrollment particular guidance. risks decided enrollment the continue, in hold by this patients these with based well. already who the new posed as protocol
NYX-XXX plans at are our investigation of and deficits patients this we on timelines t eager for to appropriate, cognitive When a reinitiate future and date. program we forward in look updates with our providing
and evaluation. the on we I that way the pandemic employees personnel our to the the of while and decisions studies safety has patients conducting of remained each forefront emphasize proceed consider of impact with health informed business, As at our study. of involved in The these COVID-XX factors on throughout best want our multiple how our to
of remote of Xth. protocols working and governor, stay Aptinyx' to order some we employees for effect ahead at and travel issued remains XXst at by Illinois instituted restrictions regards the least ago, our operations, which March weeks With home as in April
supply shipping to pandemic, of before have the escalation [ph] accelerate our for TAD investigational our steps facilitate we the uninterrupted to to taken studies. US of Fortunately, the products
to the an but We present we time. to any extended continue will comfortable effects at potential where track of about we supply regard with are disruption, feel
financing participation $XX also very position. health And The multiple have million stock we of we net and dedicated strong new, proceeds healthy as of the investors adding to care completed are quality of a balance. support the fortunate a to cash strong our already We number to existing were included pleased of sheet have a offering, well. investors. importantly In January, common balance cash approximately
course current we we that can financial into our ultimately multiple number regards studies. results, expect a to different provide expect data of enable Including But us of under will guidance to clinical that with We the XXXX. updated timing we provide cash of runway anticipate scenarios. following financing, our will clinical it of our and readouts hope the that runway with data resumption
call to I turn financial Ashish will over and end year to results. quarter now fourth the our review
